Drugs / AZD9056
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 14 trials | ||||||
| Phase 1 | NCT00908934 | May → Jul 2009 | — | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT00920608 | May → Sep 2009 | rheumatoid arthritis | AstraZeneca | Withdrawn | No outcome recorded |
| Phase 1 | NCT00736606 | Aug → Sep 2008 | — | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT00700986 | Jun → Aug 2008 | rheumatoid arthritis | AstraZeneca | Completed | No outcome recorded |
| Phase 21 trial · 1 missed | ||||||
| Phase 2 | NCT00520572 | Aug 2007 → Mar 2009 | rheumatoid arthritis | AstraZeneca | Completed | Missed primary |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AZD9056 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00908934 ↗ |
| Action | Inhibit | “The P2X(7) purinergic receptor antagonist AZD9056” PMID 22966146 ↗ Oct 20121“P2X purinoceptor 7 antagonist” CHEMBL3545108 ↗ |
| Modality | Small molecule | — CHEMBL3545108 ↗ |
| Route | Oral | “orally administered AZD9056” PMID 22966146 ↗ Oct 2012 |
| Target | P2RX7 | “P2X purinoceptor 7 antagonist” CHEMBL3545108 ↗ |